Conference Calendar

March 14-18 - American Association of Orthopaedic Medicine Annual Meeting 2017

March 14-December 31 - Canaccord Genuity Musculoskeletal Conference

Complete Calendar »

Earnings Calendar

No Upcoming Events Scheduled
Complete Calendar »

Read our research via:
email art

Weekly Email

rss art


app icon


app store icon


Orthopedic and Dental Industry News Complete Archive »

Musculoskeletal News Roundup 13-Oct-16 BY BLAKE MOSSY, OCTOBER 13, 2016

Norgine Ventures B.V., which is part of Norgine, a European specialist pharmaceutical company, entered into an agreement to acquire SpineVision SA. The company develops products that treat spinal pathologies such as lumbar degenerative disc diseases, deformities, cervical disorders, trauma and tumors. The transaction enables SpineVision to strengthen its research and development capabilities and grow the commercial activity of the company's systems that utilize dynamic stabilization and minimally invasive technologies.

Spineology received 510(k) clearance from the FDA for the use of allograft bone with its Rampart Interbody Fusion Devices. The clearance allows allografts from the Musculoskeletal Transplant Foundation (MTF) to pair with the Rampart product line, and is a delivery platform for Spineology's Incite Cortical Fiber bone graft.

Arthrosurface launched its CheckMATE 3.0, a fusion plate for the treatment of end-stage toe arthritis. The low-profile, rigid design has proven to be faster to implant versus other systems, leading to lower hospital costs and OR time and is indicated to minimize post-operative irritation and the need for secondary surgery for hardware removal.

Episurf Medical launched its surgical training simulation on the Touch Surgery application, a mobile procedural simulation system, allowing surgeons to practice Episealer's surgical technique at their convenience. Episealer's platform is a patient-specific approach to address knee lesions and previously untreatable joint pain problems. The Touch Surgery application provides surgeons with three different simulations, Episealer Condyle Solo, Episealer Trochlea Solo and Episealer Femoral Twin approaches.

Lattice Biologics launched its AminoVisc, an allograft amniotic viscosupplement for the treatment of joint pain associated with osteoarthritis (OA). Results from the Western Institutional Review Board's (WIRB) 275-patient study to assess efficacy and safety, demonstrated significant pain relief and a reduced number of adverse events as compared with traditional hyaluronic acid viscosupplements. AminoVisc is made of hyaluronan from human amniotic fluid that has similar components to human synovial fluid, and as a result, restores correct pH levels for the patients synovium to recover and slow progression of OA.

Exactech announced the first successful surgery using its Vantage Total Ankle system for the treatment of patients who suffer from arthritis in the ankle. The device's press-fit bone cage design allows stability and mobility during total ankle arthroplasty and aims for initial and long-term fixation. This ankle system represents the company's expansion into the foot and ankle market.

Exactech completed the successful first U.S. revision knee procedure using its ExactechGPS Guided Personalized Surgery system, indicated for use in skeletally mature patients undergoing surgery for total knee replacement. The system aims to provide a real-time, patient-specific solution for surgeons preforming revision knee procedures.

Xtant Medical appointed Carl O’Connell as the company's President. The position is responsible for leading all commercial efforts of Xtant, and reports to Dan Goldberger, the company's Chief Executive Officer. Mr. O’Connell most recently worked as Global Vice President of Marketing for Wright Medical in their Foot and Ankle division.

Email this to a colleague: